Skip to main content
Premium Trial:

Request an Annual Quote

Recent Pharmacogenomics-Related Patents

Premium
US Patent 7,115,726. Haplotype structures of chromosome 21. Inventors: David Cox, Deana Arnold. Assignee: Perlegen Sciences.
 
The invention “includes the use of any of the polymorphisms, SNP haplotype blocks or SNP haplotype patterns,” according to the patent abstract. In one embodiment, “susceptibility to a phenotype resulting from an allele or marker in linkage disequilibrium with such polymorphic forms is evaluated.” Novel therapeutic and diagnostic compounds and methods are also disclosed.
 

 
US Patent 7,115,373. Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene. Inventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito. Assignee: Genox Research.
 
“Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method,” according to the patent abstract. “As a result, a NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils.” The patent abstract claims that the gene can be “successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.”
 

 
US Patent 7,112,404. Process for high throughput DNA methylation analysis. Inventors: Peter Laird, Cindy Eads, Kathleen Danenberg. Assignee: Epigenomics.
 
Protects a high-throughput and quantitative process for determining methylation patterns in genomic DNA samples based on amplifying modified nucleic acid and detecting methylated nucleic acid based on amplification-dependent displacement of specifically annealed hybridization probes. The process is “particularly well suited for the rapid analysis of a large number of nucleic acid samples, such as those from collections of tumor tissues,” according to the patent abstract.
 

 
US Patent 7,108,978. Method for detecting a propensity of an individual to respond effectively to treatment of interferon-alpha and ribavirin combined therapy. Inventors: Jui-Lin Chen, Yuchi Hwang, Min-Pey Ding, Wen-Pi Chu, Shu-Ching Wang, Kuei-Ling Belinda Chen, Wan-Lin Yao, Kuang-Den Chen, Ding-Shinn Chen, Pei-Jer Chen, Ming-Yang Lai. Assignee: Vita Genomics.
 
Covers isolated polynucleotides that include sequences from the genomic region around the gene CD 81. These polynucleotides “include polymorphisms associated with treatment response of HCV patients to interferon-alpha and ribavirin combined therapy and are useful as the probes in screening for patients who will response to interferon-alpha and ribavirin combined therapy,” according to the patent abstract.
 

 
US Patent 7,107,155. Methods for the identification of genetic features for complex genetics classifiers. Inventor: Tony Frudakis. Assignee: DNAPrint Genomics.
 
Protects a method for selecting a combination of SNPs from a plurality of candidate SNP combinations for a gene associated with a genetic trait. “Haplotype data associated with this candidate SNP combination are read for a plurality of individuals and grouped into a positive-responding group and a negative-responding group based on whether a predetermined trait criteria for an individual is met,” according to the patent abstract. A statistical analysis on the grouped haplotype data is performed to obtain a statistical measurement. The acts of selecting, reading, grouping, and performing are repeated as necessary to identity the candidate SNP combination having the optimal statistical measurement.
 

 
US Patent 7,105,353. Methods of identifying individuals for inclusion in drug studies. Inventors: Daniel Cohen, Marta Blumenfeld, Ilya Chumakov. Assignee: Serono Genetics Institute.
 
Protects a method of selecting an individual for inclusion in a clinical trial of a drug for the treatment of Alzheimer's disease, prostate cancer, or asthma. According to the patent, the method comprises “a) obtaining a nucleic acid sample from an individual; b) constructing a nucleic acid library comprising a plurality of genomic DNA fragments that comprise the full genome of the individual or a portion of the genome of the individual; c) determining the order of the DNA fragments in the genome of the individual; d) determining the sequence of selected regions of said DNA fragments; e) identifying nucleotides in said DNA fragments that vary between individuals; f) determining the frequencies of each allele of one or more biallelic markers in individuals showing a detectable trait; g) identifying one or more alleles of said biallelic markers that are statistically associated with said detectable trait.”
 

 
US Patent 7,101,670. Polymorphic marker that can be used to assess the efficacy of interferon therapy. Inventors: Noriko Matsuyama, Masanobu Sugimoto, Michie Hashimoto, Shunji Mishiro . Assignee: Toshiba.
 
Protects a polymorphic marker found in a region of the interferon receptor gene that can be used to assess the efficacy of interferon therapy. The invention also relates to methods of assessing the efficacy of interferon therapy in an individual and means for accomplishing such a method.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.